Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Next Previous
Search
Trial Profile

Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Ramosetron (Primary) ; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms RAPA

    • Most Recent Events

    • 08 May 2018 Status changed from recruiting to completed.
    • 30 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 30 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top